Abstract Background This is a phase II subprotocol of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory soli...
Andrea T. Franson, Samara L. Potter, P. Williams et al.· The Oncologist· 0 citations
PURPOSE
Identification of discrete risk groups remains a high priority for patients with Ewing sarcoma (EWS). We sought to prospectively validate circulating tumor DNA (ctDNA) as a prognostic factor and develop clinical-molecular risk groups.
METHODS
We conducted a prospective investigator-initiated biology study for...
D. Shulman, Kelly S. Klega, Nan Chen et al.· Journal of Clinical Oncology· 0 citations
Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
A single-cell regulatory network analysis of therapy-associated cell state remodeling to inform combination strategies in osteosarcoma and single-cell profiling reveals drug effects missed by bulk efficacy measures is extended.
J. Pavisic, Chelsey M. Burke, Dao-Qi You et al.· Cancer Research· 0 citations
Across 236 whole-genome sequencing osteosarcoma samples, five genomic hotspots of clustered structural variation collectively altered in 58% of tumors were uncovered, and localized transcriptional dysregulation at hotspot event loci was found, linking these structural alterations to a less differentiated cell state.
Shreya Raman, Thorsten Kaltenbacher, David Merrell et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.